You just read:

Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)

News provided by

Allergan plc

Apr 05, 2017, 16:30 ET